with B10G5 also enhanced the efficacy of other cancer immunotherapeutic modalities, such as immune checkpoint blockade or adoptive cell-based therapy pre-clinically. Our study has launched a new avenue
samples (and some tumors) obtained from 27 lung cancer patients undergoing single/combined immune checkpoint blockade therapies. Results: In one responder, we found expansion of a single T cell clone ... oligoclonal T…
Predictive and prognostic biomarkers are vital for immune checkpoint blockade in solid tumors. Established markers include PD-L1 expression, \textit{Tumor Mutational Burden} (TMB), and Microsatellite Instability (MSI)…
Tumor biopsies show that B-NHL frequently deploys several immune escape strategies, a problem for the development of checkpoint blockade immunotherapies in these diseases. In particular, there are currently ... DLBCL…
Purpose: We aimed to explore the potential favourable roles of chemotherapy in promoting immune checkpoint blockade therapy in non-small cell lung cancer (NSCLC). Method: We combined chemotherapy gemcitabine with…
Immune checkpoint blockade plays a crucial role in mounting antitumor immunity thereby improving cancer survival. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and cytotoxic…
tumour mutation burden within solid tumours may be predictive for clinical response to immune checkpoint blockade but can be difficult to assess within routine clinical practice. This presentation discusses…
tumour mutation burden within solid tumours may be predictive for clinical response to immune checkpoint blockade but can be difficult to assess within routine clinical practice. This presentation discusses…
regulation of anti-tumor responses by immune-checkpoint blockade is a new approach for the treatment of advanced solid malignant tumors. There are some demerits to this therapy that require ... eligibility and efficacy…
insufficient T cell activity and consequently cancer progression. After the approval of immune checkpoint blockade anti-CTLA-4 and anti-PD-1 several costimulatory and coinhibitory molecules have been studied ... cancer…
osimertinib. Both patients had disease progression after osimertinib and received combination therapy of immune checkpoint blockade (nivolumab or pembrolizumab) and albumin-bound paclitaxel (Abraxane). These patients…
have emerged as one of the most common immune-related adverse events of Immune checkpoint blockade therapy with a reported incidence range of 2%-15% depending upon the Immune checkpoint ... study is to describe the…
fosters progression and drug resistance. The role of epigenetic alterations and mechanisms of immune checkpoint blockade resistance are discussed. Novel approaches like liquid biopsy, RNA-based therapies, CRISPR/Cas9…
last years, several new drugs have been launched for the treatment of cancer. Immune checkpoint blockade suppresses intrinsic down-regulators of immunity, such as cytotoxic T[1]lymphocyte Antigen ... Ligand 1 (PD-L1)…
last years, several new drugs have been launched for the treatment of cancer. Immune checkpoint blockade suppresses intrinsic down-regulators of immunity, such as cytotoxic T-lymphocyte Antigen 4 (CTLA ... Ligand 1…
neutralizing antibody also enhanced the efficacy of other cancer immunotherapeutic modalities, such as immune checkpoint blockade or cell-based therapy preclinically. Our study has launched a new avenue of cancer
tumor immunity. Patients with CLL are clear candidates for novel immunotherapies, such as immune checkpoint blockade, that try to restore the patients’ immune activity to induce therapeutic responses. Nonetheless…
emphasis on failure of most vaccines to activate therapeutic anti-tumor immunity. Recently, immune checkpoint blockade has proven effective to activate therapeutic immune responses in cancer patients by removing…
patients with melanoma. This includes the use of combination strategies, such as adding immune checkpoint blockade to a backbone of molecularly targeted therapy. Clinical trials combining these strategies are currently…